STAT3 Inhibitor XVIII
BP-1-102
CAS: 1334493-07-0
Molecular Formula: C29H27F5N2O6S
STAT3 Inhibitor XVIII - Names and Identifiers
STAT3 Inhibitor XVIII - Physico-chemical Properties
| Molecular Formula | C29H27F5N2O6S |
| Molar Mass | 626.59 |
| Density | 1.474±0.06 g/cm3(Predicted) |
| Boling Point | 749.2±70.0 °C(Predicted) |
| Solubility | DMSO: ≥ 33 mg/mL |
| pKa | 3.15±0.10(Predicted) |
| Storage Condition | Inert atmosphere,Store in freezer, under -20°C |
| In vitro study | BP-1-102 binds Stat3 with an affinity K D of 504 nM. BP-1-102 inhibits Stat3 DNA-binding activity in vitro , with an IC 50 value of 6.8±0.8 μM. It blocks Stat3-phospho-tyrosine peptide interactions and Stat3 activation at 4-6.8 μM, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8. |
| In vivo study | Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth. |
STAT3 Inhibitor XVIII - Preparation solution concentration reference
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.596 ml | 7.98 ml | 15.959 ml |
| 5 mM | 0.319 ml | 1.596 ml | 3.192 ml |
| 10 mM | 0.16 ml | 0.798 ml | 1.596 ml |
| 5 mM | 0.032 ml | 0.16 ml | 0.319 ml |
Last Update：2024-01-02 23:10:35
STAT3 Inhibitor XVIII - Reference Information
| biological activity | BP-1-102 is a small molecule inhibitor of transcription factor Stat3 with oral activity, and its IC50 value is 6.8 μM. | |
| target | STAT3 6.8 μM (IC 50 ) | |
| in vitro study | BP-1-102 binds stat3 with an affinity K D of 504 nM. BP-1-102 inhibits stat3 DNA-binding activity in vitro , with an IC 50 value of 6.8±0.8 μ m. it blocks Stat3-phospho-tyrosine peptide interactions and stat3 activation at 4-6.8 μ m, and selectively inhibits growth, survival, migration, and invasion of Stat3-dependent tumor cells. BP-1-102-mediated inhibition of aberrantly active Stat3 in tumor cells suppresses the expression of c-Myc, Cyclin D1, Bcl-xL, Survivin, VEGF, and Krüppel-like factor 8. | |
| in vivo research | Mick therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth. |
Last Update：2024-04-10 22:29:15
Supplier List
Spot supply
Product Name: BP-1-102 Visit Supplier Webpage Request for quotationCAS: 1334493-07-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
Spot supply
Product Name: BP-1-102 Visit Supplier Webpage Request for quotationCAS: 1334493-07-0
Tel: 18301782025
Email: 3008007409@qq.com
Mobile: 18021002903
QQ: 3008007409
Wechat: 18301782025
View History